Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
glp-1 obesity drug updates today 3 Takeaways from the Landmark Oral 'Switch' Trial for Care GLP1 Sample collection:Walk-in clinic New GLP-1 Pill Foundayo
New GLP-1 Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity
Among these potential key players, Roche continues to stand out with multiple obesity candidates within its pipeline, all in phase II trials (as of November 2025), and it is expected to enter the market in 2029 or later
GLP1
Sample collection:Walk-in clinic
doi: 10.1038/nrendo.2012.140 60 KhatDZHusainM
